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Abstract
Two different lines of osteoblast-like cells were used to investigate the effect of advanced glycation end-products of bovine
serum albumin on cell proliferation and differentiation. These parameters were found to be both dose- and time-dependent.
Cell proliferation remained unchanged after a 24 h incubation period, it increased after intermediate periods of incubation with
advanced glycation end-products, but was found to be depressed after several days incubation. Cellular alkaline phosphatase
activity followed a similar pattern: an initial increase induced by advanced glycation end-products was generally followed,
after relatively long incubation periods, by a slight but significant decrease in this parameter. 45Ca2+ uptake was only signifi-
cantly inhibited by advanced glycation end-products after 24 h incubation. These results suggest that advanced glycation end-
products directly regulate osteoblast proliferation and differentiation in a dose and time dependent manner. (Mol Cell Biochem
170: 43–51, 1997)
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Introduction
In young developing patients with insulin-dependent Diabe-
tes mellitus (IDDM), chronic hyperglycaemia is associated
with a deficit in bone mass [1–8]. Delay in maturation and
growth impairment have also been described in the most se-
verely affected patients [2]. These defects appear to be related
with a failure to acquire sufficient endosteal bone during
growth, and to nutritional, hormonal and vascular factors [9–
12]. Animal models have been used to study the influence of
Diabetes mellitus on bone metabolism [13], however, its ef-
fect on individual bone-derived cell types is poorly understood.
One of the mechanisms involved in the development of
diabetic complications is the accelerated non-enzymatic
glycosylation (glycation) of proteins, which leads to an ex-
cessive formation of advanced glycation endproducts (AGE)
[14–17]. These AGE products are irreversibly attached to
their associated proteins, altering both their structure and
bioactivity. The AGE moieties are specifically recognized by
plasma membrane receptors in cells from various tissues [18,
19]. The occupation of these specific receptors by AGE in-
duces the secretion of cytokines and growth factors, which
in turn lead to an alteration in the proliferation and differen-
tiation of nearby cells [20–22]. The excessive accumulation
of protein-AGEs in diabetic non-insulin-dependent tissues
could thus contribute to the proliferative/degenerative altera-
tions typical of diabetic complications [23, 24].
It has recently been shown that collagen-linked fluores-
cence, a measure of nonenzymatic collagen cross-linking due
to AGE formation, increases significantly in rat cortical bone
both with diabetes and age [25]. Locatto et al. [26] have also
found increased bone collagen glycation, and increased re-
sistance of bone collagen to collagenase hydrolysis, in al-
loxan-induced diabetic rats. The effect of AGE on a model
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of demineralized bone-matrix-induced endochondral bone
formation was investigated by Fong et al. [27]. They found
that the formation of AGE on bone matrix alters its ability to
induce bone formation. This experimental evidence suggests
that AGE-formation, as a consequence of high glucose lev-
els either in vivo or in vitro, may be an important factor af-
fecting bone development. However, the direct effect of
protein-AGEs on bone-derived cell types in culture has not
been studied previously.
In this study we investigate the effect of AGE products on




Fatty acid-free bovine serum albumin (BSA) (Sigma) was
incubated in phosphate buffered saline (PBS) pH 7.4, with
100 mM glucose-6-phosphate (G-6-P) at 37°C for 6 weeks
in the presence of protease inhibitor 1.5 mM phenylmethyl-
sulfonyl fluoride, and antibiotics (100 U/ml penicillin – 100
µg/ml streptomycin). This procedure has been previously
applied using alternatively glucose or G-6-P [18, 28, 29].
Control BSA was incubated under the same conditions with-
out G-6-P. At the end of the incubation period, BSA and
AGE-BSA were separated from low molecular weight mol-
ecules by centrifugation/filtration with Centricon 10 kDa cut-
off filter cartridges. The formation of AGE was assessed by
its characteristic fluorescence-emission maximum at 420 nm
upon excitation at 340 nm, using an Aminco-Bowman
SPF100 spectrofluorometer equipped with an off-axis Ellip-
soidal Mirror Condensing System and an Aminco Ratio Pho-
tometer. The excitation source was an 150W Xenon arc lamp
and the detector was an RCA 4837 photomultiplier tube.
Standard l × l cm quartz cells were used and spectra were
recorded on a Linseis 1600 x-y recorder [14]. Quinine (1 µg/
ml) was used as a fluorescence intensity standard to calibrate
and monitor the performance of the fluorescence spectropho-
tometer. Fluorescence values of test substances were ex-
pressed as percentage relative fluorescence.
Cell culture
UMR106 rat osteosarcoma-derived cells were grown in 75
cm2 plastic flasks at 37°C in a humidified 5% CO2 atmosphere
in Dulbecco’s modified Eagle’s Medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), 100 U/ml peni-
cillin and 100 µg/ml streptomycin. This cell line has been
shown to conserve certain characteristics of osteoblast phe-
notype [30]. After 5–7 days, the cells were subcultured us-
ing trypsin-EDTA to replate the cells and begin the experi-
ments. Cells were split at subconfluence and plated in 24-well
plates (2.5 104 cells/well) in 10% FBS-DMEM. Subconfluent
cells were serum deprived, washed with DMEM and incu-
bated in 0.5 ml DMEM/well with either BSA or AGE-BSA
(50–1000 µg/ml), for different incubation periods. These
doses were chosen since the bioactivity of AGE-products
occur at these concentrations in cells which have been dem-
onstrated to possess AGE receptors [20, 21, 31]. Similarly,
5–1000 µg/ml AGE-BSA have been previously used for the
displacement of 125I-AGE-BSA in radioreceptor competition
studies [18, 32]. At the end of each incubation, cells were
washed twice with PBS and processed for differentiation and
proliferation assays.
MC3T3E1 mouse calvaria-derived cells were grown in
DMEM-10% FBS and antibiotics, and passaged every 3–4
days. Previous studies have demonstrated that expression of
osteoblastic markers begins after incubating these cells for
15 days with medium supplemented by 5 mM β-glycerol
phosphate and 25 µg/ml ascorbic acid [33]. However, the
cells only undergo active replication during the first two
weeks of incubation. Thus, in order to test the effect of AGE
on the proliferation and differentiation of this cell line, dif-
ferent protocols were chosen. For studies characterizing the
effect of protein-AGE on cell proliferation, cells were plated
in 24-well plates (2.0 104 cells/well) and cultured for 2 days
in 10% FBS-DMEM. After this period, they were serum
deprived and incubated with either BSA or AGE-BSA as
described for UMR106 cells. To assess the effect of protein-
AGE on MC3T3E1 differentiation, cells were cultured in
10% FBS-DMEM media supplemented with 5 mM β-glyc-
erol phosphate and 25 µg/ml ascorbic acid for 4 weeks,
changing the medium every 3 days. This medium was then
replaced for DMEM without serum and different concentra-
tions of either BSA or AGE-BSA, and incubated for differ-
ent periods of time as before. Osteoblastic phenotype was
evaluated by alkaline phosphatase activity.
Cell proliferation bioassay
The crystal violet mitogenic bioassay [34] was carried out
as we have described previously [35]. Briefly, cells were
fixed with 5% glutaraldehyde and stained with 0.5% crys-
tal violet. Absorbance was read at 540 nm after dye extrac-
tion with glycine/HCl buffer, pH 3.0/30% methanol. We
have previously shown that the absorbance values obtained
with the crystal violet assay correlate directly with the cell
count (r = 0.897, p < 0.001) [35].
45
Cell differentiation assay: Alkaline phosphatase specific
activity (ALP)
The cell monolayer was solubilized in 0.5 ml 0.1% Triton-
X100. Aliquots of the total cell extract were saved for pro-
tein determination using the Bradford method [36], and for
measurement of ALP as we have described previously [35].
ALP is known to be a marker of mature osteoblast pheno-
type and this method has been extensively used to assess
differentiation in these cell types [35, 37].
Calcium uptake
45Ca2+ uptake was measured by incubating cells with 45CaCl2
(28 Ci/mmol, DUPONT), 0.5 µCi/ml at 37°C/30 min. After
this incubation, cells were rinsed twice with cold PBS and
solubilized with 0.1% Triton-X100. An aliquot was saved for
protein determination. The remaining extract was counted by
liquid scintillation counting [33].
Statistical analysis
At least three experiments were run by triplicate for each
experimental condition. Results are expressed as percentage
of control BSA, X ± SEM, n = number of cases. Statistical
analysis of the data was performed employing Student’s t test.
Results
The incubation of BSA with 100 mM G-6-P for prolonged
periods of time, resulted in the formation of AGE-modified
BSA (AGE-BSA). The appearance of this adduct was deter-
mined spectrofluorometrically and typical fluorescence-emis-
sion spectra for BSA and AGE-BSA are shown in Fig. 1.
Cultured osteoblast-like cells were subsequently exposed to
either BSA or AGE-BSA at different doses (50–1000 µg/ml),
and for different periods of time (24, 48, 72 or 120 h). Cell
proliferation and differentiation were evaluated at the end of
each incubation, as described in Materials and methods.
Effect of AGE on osteoblast-like cell proliferation
To assess the time-dependent patterns of AGE-BSA effect on
cell proliferation, UMR106 and MC3T3E1 osteoblast-like
cells were incubated for different periods of time after expo-
sure to 200 µg/ml BSA or AGE-BSA as described in Mate-
rials and methods. Figure 2 shows that AGE induced a
biphasic effect: cell proliferation was stimulated as early as
48 h after exposure to AGE-BSA in both cell lines. This ef-
fect disappeared with longer incubations: a slight but statis-
tically significant inhibition of UM106 cell proliferation was
detected after 3 days of incubation with AGE-BSA, while a
similar effect occured after 5 days of incubation in the case
of MC3T3E1 cells.
The effect of different AGE-BSA concentrations on cell
proliferation was investigated after 2 days of incubation. AGE-
BSA (100–500 µg/ml) significantly stimulated UMR106 cell
proliferation in a biphasic manner, ranging from 112–118
% of control BSA (Fig. 3A). On the other hand, AGE-modi-
fied BSA induced a dose-dependent increase in MC3T3E1
cell proliferation (Fig. 3B), ranging from 107–112% of
control BSA.
Effect of AGE on osteoblast-cell differentiation
In order to evaluate the effect of AGE-protein on the differ-
entiation of osteoblast phenotype, cells were incubated for
1–3 days in the presence of either BSA or AGE-BSA at dif-
ferent doses.
After 24 h incubation, AGE-BSA increased UMR106 cell
differentiation in a dose-response manner, as assessed by the
specific activity of ALP (Fig. 4A). This effect was in the range
of 125–245% over control BSA. After 48 h incubation, there
were no significant differences between the effect of BSA and
AGE-BSA on cell differentiation. A longer incubation period
(i.e. 72 h) in the presence of AGE-BSA induced a significant
inhibition of ALP activity, ranging from 83–85% of control
BSA (p < 0.01) (data not shown).
The effect of AGE-protein was also investigated in the
normal MC3T3E1 osteoblast-like cells. In this line, a
biphasic stimulation of cell differentiation was observed
after 72 h incubation in the presence of 100–500 µg/ml
AGE-BSA (Fig. 4B). However, no differences were found
between the effect of AGE-BSA and BSA on MC3T3E1 cells
at 24 and 48 h incubation (data not shown).
Effect of AGE on calcium uptake
Calcium uptake experiments were performed to test the par-
ticipation of Ca2+ in the regulation of the proliferation and/
or differentiation of UMR106 osteoblast-like cells by protein-
AGEs. After 24 h incubation, AGE-BSA inhibited 45Ca2+
uptake at 100 and 200 µg protein/ml, compared to BSA (Ta-
ble 1). A slight though non-significant decrease was observed
at 500 and 1000 µg/ml, suggesting a biphasic regulation of
calcium uptake. These changes in 45Ca2+ uptake were in-
versely associated with the ALP activity of UMR106 cells
incubated under the same conditions. A similar study was per-
formed after incubating the cells for 48 and 72 h with either
BSA or AGE-BSA in the media. No significant differences
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Fig. 1. Fluorescence-emission spectra of BSA and AGE-BSA (λexcitation = 340 nm).
Fig. 2. Time course of AGE-BSA effect on UMR106 and MC3T3EI cell proliferation. Cultures were exposed to 200 µg/ml of control BSA (● ) or AGE-
BSA for either UMR106 (▲) or MC3T3E1 (n) osteoblast-like cells, for different incubation periods. After this incubation, cell proliferation was assessed by
the cristal violet bioassay. Differences between AGE-BSA and control BSA are: #p < 0.05; *p < 0.001.
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Fig. 3. Cell proliferation of UMR106 (A) and MC3T3E1 (B) osteoblast-like cells incubated with BSA or AGE-BSA for 48 h (n = 9), Differences between
BSA and AGE-BSA are: #p < 0.01, **p < 0.002, *p < 0.001.
were found for these incubation periods and over the range
of protein concentrations tested. However, a trend by AGE-
BSA to increase 45Ca2+ uptake was observed after 48 h incu-
bation at all the protein concentrations assayed (112–140%
control BSA).
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Fig. 4. Effect of BSA or AGE-BSA on ALP specific activity of UMR106 (A) and MC3T3E1 (B) osteoblast-like cells incubated for 24 h (n = 12) and 72 h
(n = 6), respectively. Differences between BSA and AGE-BSA are: #p < 0.02, **p < 0.01, *p < 0.001.
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Discussion
Our present results show a direct effect of AGE-BSA on the
proliferation and differentiation of cultured osteoblast-like
cells. Despite intense research, few AGE molecular structures
are known in detail, and of these fewer still have been dem-
onstrated to exist in vivo. We chose to prepare AGE-protein
by means of a prolonged incubation of BSA and Glucose-6-
phosphate, because this leads to the formation of a mixture
of intermediate and late AGEs that is believed to be repre-
sentative of the spectrum of adducts existing in vivo [38].
Moreover, AGE-BSA has been extensively used to study the
changes induced by protein advanced glycation endproducts
on several cell lines and tissues [18, 28, 29, 38].
The effect of AGE-BSA on osteoblast-like cell prolifera-
tion, assayed by the crystal violet method, was time-depend-
ent (Fig. 2): it remained unchanged after relatively short
incubation periods (24 h), increased after intermediate peri-
ods (2 or 3 days for UMR106 or MC3T3E1 cells, respec-
tively), but was found to be depressed after 3 or 5 days
incubation. These results suggest that AGE-BSA induces an
early and transient mitogenic effect on osteoblast-like cells,
followed by an impaired osteoblastic progression. Further-
more, the increase in cell proliferation induced by protein-
AGE was dependent on its concentration in the culture media
(Fig. 3). This stimulation was observed in a narrow range of
concentrations (100–500 µg/ml) in the UMR106 osteosar-
coma-derived cells, whereas it was dose-dependent in the
normal MC3T3E1 osteoblast-like cultures.
When ALP activity was studied, cells exposed to AGE-
BSA initially increased their ALP specific activity. This was
observed when UMR106 or MC3T3E1 cells were incubated
for 24 or 72 h respectively (Fig. 4). However, longer culture
periods neutralized this short-term increase and finally lead
to a decrease in UMR106 ALP activity (72 h). Analysis of
the dose relationship shows a difference between the two cell
lines. A dose-dependent response was observed in the oste-
osarcoma line whereas a biphasic response to AGE-BSA was
detected in the normal osteoblastic cell line.
With the exception of the increase in alkaline phosphatase
specific activity after 24 or 72 h for UMR106 or MC3T3E1
cells, respectively, all of the observed effects were relatively
small. However, they are of the same order as those observed
after the incubation of UMR106, MC3T3E1 [35, 41] or pri-
mary osteoblast cultures with growth factors and insulin-
mimetic compounds [35, 41, 42]. Thus, these results seem
to indicate that AGE-proteins could act as weak mitogens in
the absence of serum in osteoblastic cells in culture.
The binding of protein-AGE to specific plasma membrane
receptors has been demonstrated in different systems. For in-
stance, endothelial cells [31], mesangial cells [19], fibroblasts
[24] and mouse monocyte-derived RAW 264.7 cells have been
shown to possess these specific receptors. In this last cell line
[40], the measured binding constant was identical to that of
murine peritoneal macrophages (3.1 107 M–1) [18, 32]. In these
experiments, concentrations of AGE-BSA between 5 and 1000
µg/ml were used to displace an 125I-AGE-BSA radioligand. In
our experiments with osteoblast-like cultures, the AGE-BSA
doses we used were in the same range as those of the com-
petition studies above mentioned. Even though the presence
of an AGE-receptor has not been demonstrated in osteoblastic
cells, the pattern of certain observed effects such as the time-
course, dose-dependence and the nature of AGE-protein
employed, are similar to those observed in cells known to
possess AGE-receptors [19, 21, 24, 31].
Several studies have established that in vitro AGE-modified
proteins regulate cell proliferation. Thus, AGE induces
monocytes to synthesise and release beta interleukin-1 (IL-1β),
alpha tumor necrosis factor (TNF-α), platelet-derived growth
factor (PDGF) and insulin-like growth factor I (IGF-I) [21].
These factors seem to mediate a growth promoting pathway
initiated by the binding of AGE to its specific receptor. From
time-dependent course studies, it was determined that the
IGF-I mRNA increase appeared after 48 h of AGE-exposure.
Furthermore, this induction of IGF-I mRNA was dependent
on the concentration of AGE-BSA added, up to 250 µg/ml.
Since IL-1β and TNF-α appeared earlier and disappeared
within 12 h of cell exposure to protein-AGE, these authors
suggest that AGE induces IGF-I indirectly through the release
of other cytokines. This mechanism could also occur in os-
teoblast-like cells, in which IGFs are known to be secreted
and are important regulators of cell growth [35, 39]. Simi-
larly, studies carried out with fibroblasts have demonstrated
an increase in the mitogenicity of these cells after exposure
to AGE modified matrix [24]. In a rat smooth muscle cell cul-
ture, an increase in cell proliferation was observed after the
specific binding of AGE-modified proteins to their plasma
membrane receptors [24]. It has been suggested that these
effects could occur via cytokines or growth factors secreted
by the cells.
We examined the role of Ca2+ in the regulation of differ-
entiation and proliferation of UMR106 osteoblast-like cells
by AGE-BSA. Our results indicate that low concentrations
of AGE-BSA (100–200 µg/ml) decrease calcium uptake af-
ter 24 h incubation. These results support the AGE-induced
Table 1. 45Ca2+ uptake by UMR106 cells cultured with AGE-BSA for 24 h
AGE-BSA [µg/ml] % control BSA p values
(n = 9) (vs control BSA)
100 42 ± 10 < 0 001
200 62 ± 8 < 0 05
500 73 ± 7 N.S.
1000 80 ± 8 N.S.
N.S.: not significant.
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decrease of calcium uptake reported by Fong et al. in a model
of demineralized bone-matrix-induced endochondral bone
formation [27]. We found no significant changes in calcium
uptake at longer incubation periods. Nevertheless, the altera-
tions induced by AGE-BSA in this parameter appear to fol-
low the same temporal sequence as found in the proliferative
effect in UMR106 cells, namely, an increase from 24–48 h
while decreasing after longer incubation periods. Since this
assay represents a balance between Ca2+ intake mechanisms
(via calcium channels) and Ca2+ extrusion pathways (Ca2+-
ATPase and to a lesser extent Na+/Ca2+ exchange) [43], any
of these mechanisms could be the target of AGE-protein regu-
lation in UMR106 cells.
Our present study is compatible with a long-term delete-
rious effect of AGEs on osteoblast development. Altogether,
our data are in agreement with the observation that in vitro
formation of AGE on bone matrix leads to an inhibition of
osteoblast maturation in a model of demineralized bone-ma-
trix-induced endochondral bone formation [27], and with the
reported defects in growth velocity in diabetic animals [13]
as well as in human diabetic subjects [1–8].
Our results open the question of the physiological rel-
evance and the possible role of AGE-protein accumulation
in diabetic bone matrix. Recently, Tomasek et al. [25] dem-
onstrated an increase of collagen-linked fluorescence in cor-
tical bone of diabetic versus control rats. This increase in
fluorescence intensity was approximately two-fold. However,
the concentration of collagen-AGE in this tissue cannot be
accurately estimated by this method, since apparently the
most important fluorophores in the AGE family are its early
intermediate compounds [32]. This could be done by using
either polyclonal immunoassays or a radio-receptor assay for
AGE [32]. Nevertheless, the impact of protein-AGE on bone
turnover, if it is relevant in vivo, will not only depend on its
concentration but also on the time of exposure of the bone
cells to the AGE products. Our results seem to indicate that
the normal balance between bone resorption and formation
could be perturbed by exposure of osteoblast cells to an ex-
cess of AGE-protein adducts.
Protein advanced glycation endproducts have been
strongly implicated in the initiation and acceleration of
chronic complications in diabetes [24]. Recently, it has been
suggested that AGE-induced damage is initiated, in most
cases, by an interaction with cell-membrane receptors spe-
cific for AGE [18, 19, 24, 31, 32, 40]. Although such a
receptor has not been described in osteoblast-like cells, the
effects which we now report could be accounted by such a
mechanism.
In summary, this study has provided evidence for a direct
effect of advanced glycation products on osteoblast-like cells,
suggesting a role for protein-AGEs in the pathogenesis of
bone alterations in uncompensated diabetic patients.
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